Zealand Pharma A/S
CSE:ZEAL
Zealand Pharma A/S
Total Receivables
Zealand Pharma A/S
Total Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Zealand Pharma A/S
CSE:ZEAL
|
Total Receivables
kr291m
|
CAGR 3-Years
38%
|
CAGR 5-Years
79%
|
CAGR 10-Years
24%
|
|
|
Genmab A/S
CSE:GMAB
|
Total Receivables
kr6.7B
|
CAGR 3-Years
25%
|
CAGR 5-Years
17%
|
CAGR 10-Years
51%
|
|
|
Ascendis Pharma A/S
NASDAQ:ASND
|
Total Receivables
€177.4m
|
CAGR 3-Years
97%
|
CAGR 5-Years
101%
|
CAGR 10-Years
54%
|
|
|
B
|
Bavarian Nordic A/S
CSE:BAVA
|
Total Receivables
kr1.2B
|
CAGR 3-Years
40%
|
CAGR 5-Years
78%
|
CAGR 10-Years
19%
|
|
|
Bioporto A/S
CSE:BIOPOR
|
Total Receivables
kr17.1m
|
CAGR 3-Years
7%
|
CAGR 5-Years
9%
|
CAGR 10-Years
10%
|
|
|
Saniona AB
STO:SANION
|
Total Receivables
kr15m
|
CAGR 3-Years
10%
|
CAGR 5-Years
12%
|
CAGR 10-Years
17%
|
|
Zealand Pharma A/S
Glance View
Zealand Pharma A/S is a Danish biotechnology company that has carved a niche in the medical field by focusing on the design and development of innovative peptide-based medicines. Established in 1998 and headquartered in Copenhagen, the company is driven by a singular mission: to improve patients' lives through impactful treatments. Zealand's expertise lies in peptide therapeutics, a compelling segment of biopharmaceuticals due to their ability to mimic biological processes with high specificity and efficacy. The company has a keen focus on addressing unmet medical needs, particularly in the treatment of metabolic and gastrointestinal diseases. With a robust pipeline that ranges from early-stage research to late-stage clinical trials, Zealand Pharma leverages its proprietary technology to discover and develop novel pharmaceuticals that can be game-changers in their respective therapeutic areas. Zealand Pharma's business model centers around the development and commercialization of its proprietary medicines, both independently and through strategic partnerships. By collaborating with larger pharmaceutical companies, Zealand enhances its global commercialization capabilities and mitigates the financial risks inherent in drug development. For instance, the company has partnered with multinational corporations, allowing it to tap into resources for advanced research, regulatory processes, and worldwide distribution systems. Revenue streams are diversified through milestone payments, royalties, and direct sales, ensuring a steady inflow of cash that supports continued innovation. This strategic approach not only sustains its operations but also propels its mission of delivering transformative healthcare solutions. In essence, Zealand Pharma thrives at the confluence of science and strategy, driving both its financial health and its contributions to the biopharmaceutical landscape.
See Also
What is Zealand Pharma A/S's Total Receivables?
Total Receivables
291m
DKK
Based on the financial report for Dec 31, 2024, Zealand Pharma A/S's Total Receivables amounts to 291m DKK.
What is Zealand Pharma A/S's Total Receivables growth rate?
Total Receivables CAGR 10Y
24%
Over the last year, the Total Receivables growth was 163%. The average annual Total Receivables growth rates for Zealand Pharma A/S have been 38% over the past three years , 79% over the past five years , and 24% over the past ten years .
You don't have any saved screeners yet